Evidence map›Paper›PMID 32391254›Full record

ArticleFrontiers in oncology2020

Successful Treatment of Early Relapsed High-Risk AML After Allogeneic Hematopoietic Stem Cell Transplantation With Biomodulatory Therapy.

Anna-Sophia Kattner, Ernst Holler, Wolfgang Herr, Albrecht Reichle, Daniel Wolff, Daniel Heudobler

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Drug Repurposing by Tumor Tissue Editing.Frontiers in oncology · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Anna-Sophia KattnerDepartment of Internal Medicine III, Hematology and Internal Oncology, University Hospital Regensburg, Regensburg, Germany.
Ernst HollerDepartment of Internal Medicine III, Hematology and Internal Oncology, University Hospital Regensburg, Regensburg, Germany.
Wolfgang HerrDepartment of Internal Medicine III, Hematology and Internal Oncology, University Hospital Regensburg, Regensburg, Germany.
Albrecht ReichleDepartment of Internal Medicine III, Hematology and Internal Oncology, University Hospital Regensburg, Regensburg, Germany.
Daniel WolffDepartment of Internal Medicine III, Hematology and Internal Oncology, University Hospital Regensburg, Regensburg, Germany.
Daniel HeudoblerDepartment of Internal Medicine III, Hematology and Internal Oncology, University Hospital Regensburg, Regensburg, Germany.
University Hospital Regensburg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Early relapse of acute myeloid leukemia (AML) after allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an often unsuccessful therapeutic challenge. Since treatment options are few and efficacy is low, new approaches such as

Indexed as

acute myeloid leukemiaallogeneic stem cell transplantationanakoinosisbiomodulatory treatmentrelapse

Identifiers

PMID32391254
PMCPMC7190808
OpenAlexW3020041510

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.